Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 7

Results For "QUANTI"

147 News Found

World’s first intra-nasal vaccine for COVID developed by India has got approval from CDSCO
News | December 02, 2022

World’s first intra-nasal vaccine for COVID developed by India has got approval from CDSCO

Phase-III trials were conducted for safety, and immunogenicity in around 3,100 subjects, in 14 trial sites across India (supported by BIRAC)


Botanical Solution and Croda Pharma inks agreement to accelerate production for GMP QS-21
News | December 01, 2022

Botanical Solution and Croda Pharma inks agreement to accelerate production for GMP QS-21

QS-21 in blockbuster Shingles vaccine, first vaccine approved for Malaria, promising RSV phase III candidate, and Covid-19 applications.


Delivery solution provider ZIM Laboratories Limited lists on NSE
News | November 26, 2022

Delivery solution provider ZIM Laboratories Limited lists on NSE

The total quantity traded at NSE stood at 34,653 shares and the total turnover stood at Rs. 117.23 lakh.


Sustaining growth momentum is key for Navin Fluorine: ICICI Securities
News | October 31, 2022

Sustaining growth momentum is key for Navin Fluorine: ICICI Securities

NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.


Cytel to acquire SDS Life Science and SDS MedteQ
News | October 14, 2022

Cytel to acquire SDS Life Science and SDS MedteQ

The move will add new global talent to Cytel’s Strategic Consulting group


Evonik and Phathom Pharmaceuticals partner to produce novel acid-blocker vonoprazan
News | October 13, 2022

Evonik and Phathom Pharmaceuticals partner to produce novel acid-blocker vonoprazan

Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)


Hester planning capacity expansion for Goat Pox vaccine
News | September 27, 2022

Hester planning capacity expansion for Goat Pox vaccine

Further, ICAR-IVRI have jointly developed a Lumpy Skin Disease vaccine and as soon as the technology is made available, Hester will acquire the same and manufacture and commercialize the Lumpy Skin disease Vaccine


Aptar Pharma collaborates with Fluidda
News | September 25, 2022

Aptar Pharma collaborates with Fluidda

The companies will leverage their respective proprietary technology platforms


Centre grants approval of three Bulk Drug Parks
Policy | September 02, 2022

Centre grants approval of three Bulk Drug Parks

The Bulk Drug Parks to be developed under the scheme will provide common infrastructure facilities at one place thereby creating a robust ecosystem for the bulk drug manufacturing in the country and also reducing manufacturing cost significantly


Abbott’s blood test for concussion could predict outcomes from brain injury and inform treatment interventions
Clinical Trials | August 18, 2022

Abbott’s blood test for concussion could predict outcomes from brain injury and inform treatment interventions

The study concluded that elevated levels of two proteins help predict how a person will recover from a traumatic brain injury (TBI), providing important information to determine appropriate care